AIM ImmunoTech (AIM) Stock Climbs On COVID-19 Collaboration

AIM ImmunoTech AIM Stock News

AIM ImmunoTech Inc (NYSEAMERICAN: AIM) is runnning for the top in the market this morning, gaining more than 50% before the opening bell. The gains are here for good reason too. The company announced that it entered into a collaboration that will allow for a seamless delivery of Ampligen to the People’s Republic of China for the treatment of COVID-19. Here’s what’s going on:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

AIM Stock Jumps On Coronavirus Collaboration

In a press release issued early this morning, AIM ImmunoTech said that it has joined forces with ChinaGoAbroad. The collaboration surrounds the facilitation of the entry of the company’s experimental drug, Ampligen, into China for use as a prophylactic/early-onset therapeutic against COVID-19.

Importantly, AIM pointed out that CGA is a member-based online information platform and offline advisory firm. The firm serves to facilitate two-way international transactions relating to Chine in collaboration witht he China Overseas Development Association.

CGA has already taken various steps to help the fight against the growing COVID-19 epidemic. In fact, the company has been assigned to assist with the international purchase of technology, masks, gowns and gloves by Sinopharm Group, a Chinese state pharmaceutical company.

In a statement, Thomas K. Equjels, CEO at AIM, had the following to offer:

AIM is working aggressively to advance the introduction of Ampligen into China, in order to provide the Chinese people with a potential first line of defense against the deadly COVID-19 virus. AIM and CGA have taken this first step to facilitate discussions with the Chinese government for Ampligen’s entry into China as a targeted prophylactic/early-onset therapy. Ampligen achieved a 100% survival rate, as compared to 100% mortality in the untreated control animals, in SARS animal experiments after the outbreak in 2003. In these experiments, Ampligen was administered to mice prior to and shortly after infection. The Company believes that Ampligen may provide similarly effective prophylaxis against COVID-19, as both coronaviruses are extremely similar in key regulatory RNA sequences essential for coronaviral replication.

Why This News Is So Important

The truth of the matter is that AIM ImmunoTech’s Ampligen has shown efficacy across a long list of ailments, as the immunotherapy helps to alter the disease microenvironment while assisting the body’s innate immune system to attack illness.

The company was one of the first to announce that it is not only working on a vaccine, but a therapeutic option to treat patients that fall in will COVID-19. Should Ampligen show efficacy in this space, and break into the Chinese market, the opportunity would be substantial.

Considering the fact that AIM stock trades with a market cap of around $15 million, breaking into this market would be a game changer for the company and all involved.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story!

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.